CONCEPTION OF A POTENT DRUG THROUGH TOXICITY AND PHARMACOPHORE STUDY FOR INHIBITING CD 1 INVOLVED IN CANCER BY MOLECULAR DOCKING STUDIES

Cancer is a class of disease, where the cells uncontrollably divide without any control over cell cycle and cell division. Various factors contribute to cause of cancer in many ways. Ultimately the cancer cell proliferates without control over cell cycle. Many factors involve in cell cycle amongst that one of the ideal target is Cyclin D1 which couples with cyclin dependent kinase 4, phosphorylates it and this complex promotes cell cycle to next phase. It has been proven that Cyclin D1 inhibition can prevent the progress of many cancers, particularly the breast cancer. So, in the present study Cyclin D1 is exclusively considered as a potent target and by using various commercial softwares and on line tools and databases a couple of drugs have been designed to bind to and inhibit Cyclin D1 and prevent the progress of cell cycle in cancerous cells, and all the designed molecules are evaluated for its pharmacokinetic properties, toxicities, potencies, pharmacophore and lastly its binding ability with the target has been studied and submitted. Considering all the necessity aspects of drug like pharmacokinetic, toxicity, and binding ability and binding energies amongst all the best molecules the ligand M718 is proven to be the best with all the acceptable properties to treat cancer